PERCEPTION AND PRACTICE OF SUBLINGUAL IMMUNOTHERAPY AMONG PRACTICING ALLERGISTS IN THE US: 2018 FOLLOW-UP SURVEY.

Introduction Limited information regarding current trends of sublingual immunotherapy (SLIT) use in the United States and perception of SLIT relative to 2007 and 2013 is available, especially in light of recent FDA-approved SLIT options. Methods On behalf the American College of Allergy, Asthma, and Immunology (ACAAI) Immunotherapy and Diagnostics Committee, an electronic survey was sent to all ACAAI allergists practicing in the United States in July 2018. Results 150 of 202 respondents (74.3%) reported experience using SLIT compared with 59 of 519 (11.4%) in 2013 (P  Conclusions There has been a six-fold increase in SLIT use in the last 5 years, with 74% of respondents reporting SLIT use. With four FDA-approved SLIT therapies, this likely contributes to its more widespread use. Current barrier to more SLIT use appears to limited by ability to only use one allergen. It is anticipated that if there was FDA-approval of SLIT that included multiple allergens, this could become a more favorable treatment option for allergists.